#USA #Cambridge #Alltrna #tRNA #Dr. Nerissa Kreher

Alltrna’s New Leadership in tRNA Medicines

Alltrna, a company at the forefront of transfer RNA (tRNA) therapeutics, recently announced an important addition to its leadership team with the appointment of Dr. Nerissa Kreher as Chief Medical Officer (CMO). With this strategic decision, Alltrna aims to accelerate its efforts in developing revolutionary tRNA-based treatments for rare diseases.

Dr. Nerissa Kreher, a physician executive and pediatric endocrinologist, brings to Alltrna a wealth of experience in rare disease drug development, encompassing critical expertise in clinical development, medical affairs, and regulatory strategy across various stages of drug programs. Her appointment is seen as pivotal, especially as the company works to progress its first tRNA development candidates for liver Stop Codon Disease into clinical trials.

Michelle C. Werner, the CEO of Alltrna, expressed enthusiasm about Dr. Kreher joining the leadership team. She emphasized that Dr. Kreher's proven ability to navigate complex regulatory environments and her dedication to advancing innovative therapies for rare diseases will be essential as they aim to deliver new treatment options to patients in need.

Dr. Kreher herself shared her excitement about this opportunity, indicating that she is honored to join Alltrna during such a crucial time. She noted that the company’s pioneering tRNA platform has the potential to facilitate the development of transformative therapies for underserved conditions, and she looks forward to collaborating with the talented team at Alltrna.

Dr. Kreher's track record in biotechnology is impressive, marked by significant leadership roles in both private and public companies focused on rare diseases. She previously held the role of CMO at Entrada Therapeutics, where she effectively directed clinical and regulatory strategies, medical affairs, and efforts to advocate for patients. In her notable career, she has significantly impacted the development and commercialization of therapies targeting neuromuscular, metabolic, and lysosomal storage disorders.

Her tenure at Tiburio Therapeutics and AVROBIO further solidified her reputation as an influential figure in gene therapy programs. Beyond her practical experience, Dr. Kreher has also made strategic contributions to high-profile deals, including a substantial acquisition involving Alexion and Enobia Pharma.

Outside of her recent appointments, she actively engages in governance through her role as an independent board member for Rezolute Bio. Her strong academic background includes an M.D. from East Carolina University School of Medicine, an M.S. in Clinical Research from Indiana University, and an Executive MBA from Northeastern University. Moreover, she is certified in Pediatric Endocrinology by the American Board of Pediatrics.

Alltrna is committed to solving the challenges associated with genetic diseases by unlocking the power of tRNA biology. Utilizing advanced technologies such as AI and machine learning, the company is developing a range of programmable molecules capable of treating various genetic conditions influenced by the same underlying mutations. Their innovative approach to tRNA medicines represents a promising horizon for rare disease treatments.

Founded in 2018 by Flagship Pioneering, Alltrna is rapidly moving towards facilitating significant advancements in the biopharmaceutical space. The company’s focus on groundbreaking therapeutic solutions positions it well to make a lasting impact on the lives of patients and the overall healthcare landscape.

For more information on Alltrna and their efforts in advancing tRNA medicines, visit www.alltrna.com.